Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very early disease stages, when neurodegeneration is limited, and can be normal in advanced...
Saved in:
| Published in | Molecular neurodegeneration Vol. 17; no. 1; pp. 27 - 16 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
28.03.2022
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1750-1326 1750-1326 |
| DOI | 10.1186/s13024-022-00521-3 |
Cover
Loading…
| Abstract | Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very early disease stages, when neurodegeneration is limited, and can be normal in advanced disease stages. This suggests that t-tau levels may be driven by other mechanisms as well. Because tau pathophysiology is emerging as treatment target for AD, we aimed to clarify molecular processes associated with CSF t-tau levels.
We performed a proteomic, genomic, and imaging study in 1380 individuals with AD, in the preclinical, prodromal, and mild dementia stage, and 380 controls from the Alzheimer's Disease Neuroimaging Initiative and EMIF-AD Multimodality Biomarker Discovery study.
We found that, relative to controls, AD individuals with increased t-tau had increased CSF concentrations of over 400 proteins enriched for neuronal plasticity processes. In contrast, AD individuals with normal t-tau had decreased levels of these plasticity proteins and showed increased concentrations of proteins indicative of blood-brain barrier and blood-CSF barrier dysfunction, relative to controls. The distinct proteomic profiles were already present in the preclinical AD stage and persisted in prodromal and dementia stages implying that they reflect disease traits rather than disease states. Dysregulated plasticity proteins were associated with SUZ12 and REST signaling, suggesting aberrant gene repression. GWAS analyses contrasting AD individuals with and without increased t-tau highlighted several genes involved in the regulation of gene expression. Targeted analyses of SNP rs9877502 in GMNC, associated with t-tau levels previously, correlated in individuals with AD with CSF concentrations of 591 plasticity associated proteins. The number of APOE-e4 alleles, however, was not associated with the concentration of plasticity related proteins.
CSF t-tau levels in AD are associated with altered levels of proteins involved in neuronal plasticity and blood-brain and blood-CSF barrier dysfunction. Future trials may need to stratify on CSF t-tau status, as AD individuals with increased t-tau and normal t-tau are likely to respond differently to treatment, given their opposite CSF proteomic profiles. |
|---|---|
| AbstractList | Abstract Background Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer’s disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very early disease stages, when neurodegeneration is limited, and can be normal in advanced disease stages. This suggests that t-tau levels may be driven by other mechanisms as well. Because tau pathophysiology is emerging as treatment target for AD, we aimed to clarify molecular processes associated with CSF t-tau levels. Methods We performed a proteomic, genomic, and imaging study in 1380 individuals with AD, in the preclinical, prodromal, and mild dementia stage, and 380 controls from the Alzheimer’s Disease Neuroimaging Initiative and EMIF-AD Multimodality Biomarker Discovery study. Results We found that, relative to controls, AD individuals with increased t-tau had increased CSF concentrations of over 400 proteins enriched for neuronal plasticity processes. In contrast, AD individuals with normal t-tau had decreased levels of these plasticity proteins and showed increased concentrations of proteins indicative of blood–brain barrier and blood-CSF barrier dysfunction, relative to controls. The distinct proteomic profiles were already present in the preclinical AD stage and persisted in prodromal and dementia stages implying that they reflect disease traits rather than disease states. Dysregulated plasticity proteins were associated with SUZ12 and REST signaling, suggesting aberrant gene repression. GWAS analyses contrasting AD individuals with and without increased t-tau highlighted several genes involved in the regulation of gene expression. Targeted analyses of SNP rs9877502 in GMNC, associated with t-tau levels previously, correlated in individuals with AD with CSF concentrations of 591 plasticity associated proteins. The number of APOE-e4 alleles, however, was not associated with the concentration of plasticity related proteins. Conclusions CSF t-tau levels in AD are associated with altered levels of proteins involved in neuronal plasticity and blood–brain and blood-CSF barrier dysfunction. Future trials may need to stratify on CSF t-tau status, as AD individuals with increased t-tau and normal t-tau are likely to respond differently to treatment, given their opposite CSF proteomic profiles. Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very early disease stages, when neurodegeneration is limited, and can be normal in advanced disease stages. This suggests that t-tau levels may be driven by other mechanisms as well. Because tau pathophysiology is emerging as treatment target for AD, we aimed to clarify molecular processes associated with CSF t-tau levels. We performed a proteomic, genomic, and imaging study in 1380 individuals with AD, in the preclinical, prodromal, and mild dementia stage, and 380 controls from the Alzheimer's Disease Neuroimaging Initiative and EMIF-AD Multimodality Biomarker Discovery study. We found that, relative to controls, AD individuals with increased t-tau had increased CSF concentrations of over 400 proteins enriched for neuronal plasticity processes. In contrast, AD individuals with normal t-tau had decreased levels of these plasticity proteins and showed increased concentrations of proteins indicative of blood-brain barrier and blood-CSF barrier dysfunction, relative to controls. The distinct proteomic profiles were already present in the preclinical AD stage and persisted in prodromal and dementia stages implying that they reflect disease traits rather than disease states. Dysregulated plasticity proteins were associated with SUZ12 and REST signaling, suggesting aberrant gene repression. GWAS analyses contrasting AD individuals with and without increased t-tau highlighted several genes involved in the regulation of gene expression. Targeted analyses of SNP rs9877502 in GMNC, associated with t-tau levels previously, correlated in individuals with AD with CSF concentrations of 591 plasticity associated proteins. The number of APOE-e4 alleles, however, was not associated with the concentration of plasticity related proteins. CSF t-tau levels in AD are associated with altered levels of proteins involved in neuronal plasticity and blood-brain and blood-CSF barrier dysfunction. Future trials may need to stratify on CSF t-tau status, as AD individuals with increased t-tau and normal t-tau are likely to respond differently to treatment, given their opposite CSF proteomic profiles. Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very early disease stages, when neurodegeneration is limited, and can be normal in advanced disease stages. This suggests that t-tau levels may be driven by other mechanisms as well. Because tau pathophysiology is emerging as treatment target for AD, we aimed to clarify molecular processes associated with CSF t-tau levels. We performed a proteomic, genomic, and imaging study in 1380 individuals with AD, in the preclinical, prodromal, and mild dementia stage, and 380 controls from the Alzheimer's Disease Neuroimaging Initiative and EMIF-AD Multimodality Biomarker Discovery study. We found that, relative to controls, AD individuals with increased t-tau had increased CSF concentrations of over 400 proteins enriched for neuronal plasticity processes. In contrast, AD individuals with normal t-tau had decreased levels of these plasticity proteins and showed increased concentrations of proteins indicative of blood-brain barrier and blood-CSF barrier dysfunction, relative to controls. The distinct proteomic profiles were already present in the preclinical AD stage and persisted in prodromal and dementia stages implying that they reflect disease traits rather than disease states. Dysregulated plasticity proteins were associated with SUZ12 and REST signaling, suggesting aberrant gene repression. GWAS analyses contrasting AD individuals with and without increased t-tau highlighted several genes involved in the regulation of gene expression. Targeted analyses of SNP rs9877502 in GMNC, associated with t-tau levels previously, correlated in individuals with AD with CSF concentrations of 591 plasticity associated proteins. The number of APOE-e4 alleles, however, was not associated with the concentration of plasticity related proteins. CSF t-tau levels in AD are associated with altered levels of proteins involved in neuronal plasticity and blood-brain and blood-CSF barrier dysfunction. Future trials may need to stratify on CSF t-tau status, as AD individuals with increased t-tau and normal t-tau are likely to respond differently to treatment, given their opposite CSF proteomic profiles. Background Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very early disease stages, when neurodegeneration is limited, and can be normal in advanced disease stages. This suggests that t-tau levels may be driven by other mechanisms as well. Because tau pathophysiology is emerging as treatment target for AD, we aimed to clarify molecular processes associated with CSF t-tau levels. Methods We performed a proteomic, genomic, and imaging study in 1380 individuals with AD, in the preclinical, prodromal, and mild dementia stage, and 380 controls from the Alzheimer's Disease Neuroimaging Initiative and EMIF-AD Multimodality Biomarker Discovery study. Results We found that, relative to controls, AD individuals with increased t-tau had increased CSF concentrations of over 400 proteins enriched for neuronal plasticity processes. In contrast, AD individuals with normal t-tau had decreased levels of these plasticity proteins and showed increased concentrations of proteins indicative of blood-brain barrier and blood-CSF barrier dysfunction, relative to controls. The distinct proteomic profiles were already present in the preclinical AD stage and persisted in prodromal and dementia stages implying that they reflect disease traits rather than disease states. Dysregulated plasticity proteins were associated with SUZ12 and REST signaling, suggesting aberrant gene repression. GWAS analyses contrasting AD individuals with and without increased t-tau highlighted several genes involved in the regulation of gene expression. Targeted analyses of SNP rs9877502 in GMNC, associated with t-tau levels previously, correlated in individuals with AD with CSF concentrations of 591 plasticity associated proteins. The number of APOE-e4 alleles, however, was not associated with the concentration of plasticity related proteins. Conclusions CSF t-tau levels in AD are associated with altered levels of proteins involved in neuronal plasticity and blood-brain and blood-CSF barrier dysfunction. Future trials may need to stratify on CSF t-tau status, as AD individuals with increased t-tau and normal t-tau are likely to respond differently to treatment, given their opposite CSF proteomic profiles. Keywords: Alzheimer's disease, Molecular mechanisms, Biomarker discovery, Heterogeneity, Neuronal plasticity, Cerebrospinal fluid proteomics Background Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very early disease stages, when neurodegeneration is limited, and can be normal in advanced disease stages. This suggests that t-tau levels may be driven by other mechanisms as well. Because tau pathophysiology is emerging as treatment target for AD, we aimed to clarify molecular processes associated with CSF t-tau levels. Methods We performed a proteomic, genomic, and imaging study in 1380 individuals with AD, in the preclinical, prodromal, and mild dementia stage, and 380 controls from the Alzheimer's Disease Neuroimaging Initiative and EMIF-AD Multimodality Biomarker Discovery study. Results We found that, relative to controls, AD individuals with increased t-tau had increased CSF concentrations of over 400 proteins enriched for neuronal plasticity processes. In contrast, AD individuals with normal t-tau had decreased levels of these plasticity proteins and showed increased concentrations of proteins indicative of blood-brain barrier and blood-CSF barrier dysfunction, relative to controls. The distinct proteomic profiles were already present in the preclinical AD stage and persisted in prodromal and dementia stages implying that they reflect disease traits rather than disease states. Dysregulated plasticity proteins were associated with SUZ12 and REST signaling, suggesting aberrant gene repression. GWAS analyses contrasting AD individuals with and without increased t-tau highlighted several genes involved in the regulation of gene expression. Targeted analyses of SNP rs9877502 in GMNC, associated with t-tau levels previously, correlated in individuals with AD with CSF concentrations of 591 plasticity associated proteins. The number of APOE-e4 alleles, however, was not associated with the concentration of plasticity related proteins. Conclusions CSF t-tau levels in AD are associated with altered levels of proteins involved in neuronal plasticity and blood-brain and blood-CSF barrier dysfunction. Future trials may need to stratify on CSF t-tau status, as AD individuals with increased t-tau and normal t-tau are likely to respond differently to treatment, given their opposite CSF proteomic profiles. Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very early disease stages, when neurodegeneration is limited, and can be normal in advanced disease stages. This suggests that t-tau levels may be driven by other mechanisms as well. Because tau pathophysiology is emerging as treatment target for AD, we aimed to clarify molecular processes associated with CSF t-tau levels.BACKGROUNDIncreased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very early disease stages, when neurodegeneration is limited, and can be normal in advanced disease stages. This suggests that t-tau levels may be driven by other mechanisms as well. Because tau pathophysiology is emerging as treatment target for AD, we aimed to clarify molecular processes associated with CSF t-tau levels.We performed a proteomic, genomic, and imaging study in 1380 individuals with AD, in the preclinical, prodromal, and mild dementia stage, and 380 controls from the Alzheimer's Disease Neuroimaging Initiative and EMIF-AD Multimodality Biomarker Discovery study.METHODSWe performed a proteomic, genomic, and imaging study in 1380 individuals with AD, in the preclinical, prodromal, and mild dementia stage, and 380 controls from the Alzheimer's Disease Neuroimaging Initiative and EMIF-AD Multimodality Biomarker Discovery study.We found that, relative to controls, AD individuals with increased t-tau had increased CSF concentrations of over 400 proteins enriched for neuronal plasticity processes. In contrast, AD individuals with normal t-tau had decreased levels of these plasticity proteins and showed increased concentrations of proteins indicative of blood-brain barrier and blood-CSF barrier dysfunction, relative to controls. The distinct proteomic profiles were already present in the preclinical AD stage and persisted in prodromal and dementia stages implying that they reflect disease traits rather than disease states. Dysregulated plasticity proteins were associated with SUZ12 and REST signaling, suggesting aberrant gene repression. GWAS analyses contrasting AD individuals with and without increased t-tau highlighted several genes involved in the regulation of gene expression. Targeted analyses of SNP rs9877502 in GMNC, associated with t-tau levels previously, correlated in individuals with AD with CSF concentrations of 591 plasticity associated proteins. The number of APOE-e4 alleles, however, was not associated with the concentration of plasticity related proteins.RESULTSWe found that, relative to controls, AD individuals with increased t-tau had increased CSF concentrations of over 400 proteins enriched for neuronal plasticity processes. In contrast, AD individuals with normal t-tau had decreased levels of these plasticity proteins and showed increased concentrations of proteins indicative of blood-brain barrier and blood-CSF barrier dysfunction, relative to controls. The distinct proteomic profiles were already present in the preclinical AD stage and persisted in prodromal and dementia stages implying that they reflect disease traits rather than disease states. Dysregulated plasticity proteins were associated with SUZ12 and REST signaling, suggesting aberrant gene repression. GWAS analyses contrasting AD individuals with and without increased t-tau highlighted several genes involved in the regulation of gene expression. Targeted analyses of SNP rs9877502 in GMNC, associated with t-tau levels previously, correlated in individuals with AD with CSF concentrations of 591 plasticity associated proteins. The number of APOE-e4 alleles, however, was not associated with the concentration of plasticity related proteins.CSF t-tau levels in AD are associated with altered levels of proteins involved in neuronal plasticity and blood-brain and blood-CSF barrier dysfunction. Future trials may need to stratify on CSF t-tau status, as AD individuals with increased t-tau and normal t-tau are likely to respond differently to treatment, given their opposite CSF proteomic profiles.CONCLUSIONSCSF t-tau levels in AD are associated with altered levels of proteins involved in neuronal plasticity and blood-brain and blood-CSF barrier dysfunction. Future trials may need to stratify on CSF t-tau status, as AD individuals with increased t-tau and normal t-tau are likely to respond differently to treatment, given their opposite CSF proteomic profiles. BACKGROUND: Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very early disease stages, when neurodegeneration is limited, and can be normal in advanced disease stages. This suggests that t-tau levels may be driven by other mechanisms as well. Because tau pathophysiology is emerging as treatment target for AD, we aimed to clarify molecular processes associated with CSF t-tau levels. METHODS: We performed a proteomic, genomic, and imaging study in 1380 individuals with AD, in the preclinical, prodromal, and mild dementia stage, and 380 controls from the Alzheimer's Disease Neuroimaging Initiative and EMIF-AD Multimodality Biomarker Discovery study. RESULTS: We found that, relative to controls, AD individuals with increased t-tau had increased CSF concentrations of over 400 proteins enriched for neuronal plasticity processes. In contrast, AD individuals with normal t-tau had decreased levels of these plasticity proteins and showed increased concentrations of proteins indicative of blood-brain barrier and blood-CSF barrier dysfunction, relative to controls. The distinct proteomic profiles were already present in the preclinical AD stage and persisted in prodromal and dementia stages implying that they reflect disease traits rather than disease states. Dysregulated plasticity proteins were associated with SUZ12 and REST signaling, suggesting aberrant gene repression. GWAS analyses contrasting AD individuals with and without increased t-tau highlighted several genes involved in the regulation of gene expression. Targeted analyses of SNP rs9877502 in GMNC, associated with t-tau levels previously, correlated in individuals with AD with CSF concentrations of 591 plasticity associated proteins. The number of APOE-e4 alleles, however, was not associated with the concentration of plasticity related proteins. CONCLUSIONS: CSF t-tau levels in AD are associated with altered levels of proteins involved in neuronal plasticity and blood-brain and blood-CSF barrier dysfunction. Future trials may need to stratify on CSF t-tau status, as AD individuals with increased t-tau and normal t-tau are likely to respond differently to treatment, given their opposite CSF proteomic profiles. |
| ArticleNumber | 27 |
| Audience | Academic |
| Author | Streffer, Johannes Engelborghs, Sebastiaan Vos, Stephanie J. B. Tijms, Betty M. Teunissen, Charlotte E. Bos, Isabelle Dobricic, Valerija van der Lee, Sven J. Lleó, Alberto Tsolaki, Magda Jansen, Iris Froelich, Lutz Dicks, Ellen Zetterberg, Henrik Bertram, Lars Verhey, Frans R. J. Sleegers, Kristel Gobom, Johan Freund-Levi, Yvonne Molinuevo, José Luís Visser, Pieter Jelle Reus, Lianne M. Blennow, Kaj Smit, August B. Popp, Julius Martinez-Lage, Pablo Vandenberghe, Rik Lovestone, Simon Scheltens, Philip |
| Author_xml | – sequence: 1 givenname: Pieter Jelle orcidid: 0000-0001-8008-9727 surname: Visser fullname: Visser, Pieter Jelle – sequence: 2 givenname: Lianne M. surname: Reus fullname: Reus, Lianne M. – sequence: 3 givenname: Johan surname: Gobom fullname: Gobom, Johan – sequence: 4 givenname: Iris surname: Jansen fullname: Jansen, Iris – sequence: 5 givenname: Ellen surname: Dicks fullname: Dicks, Ellen – sequence: 6 givenname: Sven J. surname: van der Lee fullname: van der Lee, Sven J. – sequence: 7 givenname: Magda surname: Tsolaki fullname: Tsolaki, Magda – sequence: 8 givenname: Frans R. J. surname: Verhey fullname: Verhey, Frans R. J. – sequence: 9 givenname: Julius surname: Popp fullname: Popp, Julius – sequence: 10 givenname: Pablo surname: Martinez-Lage fullname: Martinez-Lage, Pablo – sequence: 11 givenname: Rik surname: Vandenberghe fullname: Vandenberghe, Rik – sequence: 12 givenname: Alberto surname: Lleó fullname: Lleó, Alberto – sequence: 13 givenname: José Luís surname: Molinuevo fullname: Molinuevo, José Luís – sequence: 14 givenname: Sebastiaan surname: Engelborghs fullname: Engelborghs, Sebastiaan – sequence: 15 givenname: Yvonne surname: Freund-Levi fullname: Freund-Levi, Yvonne – sequence: 16 givenname: Lutz surname: Froelich fullname: Froelich, Lutz – sequence: 17 givenname: Kristel surname: Sleegers fullname: Sleegers, Kristel – sequence: 18 givenname: Valerija surname: Dobricic fullname: Dobricic, Valerija – sequence: 19 givenname: Simon surname: Lovestone fullname: Lovestone, Simon – sequence: 20 givenname: Johannes surname: Streffer fullname: Streffer, Johannes – sequence: 21 givenname: Stephanie J. B. surname: Vos fullname: Vos, Stephanie J. B. – sequence: 22 givenname: Isabelle surname: Bos fullname: Bos, Isabelle – sequence: 23 givenname: August B. surname: Smit fullname: Smit, August B. – sequence: 24 givenname: Kaj surname: Blennow fullname: Blennow, Kaj – sequence: 25 givenname: Philip surname: Scheltens fullname: Scheltens, Philip – sequence: 26 givenname: Charlotte E. surname: Teunissen fullname: Teunissen, Charlotte E. – sequence: 27 givenname: Lars surname: Bertram fullname: Bertram, Lars – sequence: 28 givenname: Henrik surname: Zetterberg fullname: Zetterberg, Henrik – sequence: 29 givenname: Betty M. surname: Tijms fullname: Tijms, Betty M. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35346299$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-98330$$DView record from Swedish Publication Index https://gup.ub.gu.se/publication/315298$$DView record from Swedish Publication Index |
| BookMark | eNp9kstu1DAUhiNURC_wAixQJDZdkOJbfNkgjYZbpUpsgK3lOCczHpI42EmrsuI1eD2eBGemhU4FyAtbx9__28f-j7OD3veQZU8xOsNY8pcRU0RYgQgpECoJLuiD7AiLEhWYEn5wZ32YHce4QYiJBD7KDmlJGSdKHWXDEgJUwcfB9abNm3ZydT6aKW_hEtqYmwC5idFbZ0ao8ys3rnNT9T50ie5hCn6WDa2Jo7NuvM47E75AiLnr80X7bQ2ug_Dz-4-Y1y6CifA4e9iYNsKTm_kk-_T2zcfl--Liw7vz5eKisFzwsQCLbEMqSwWBGjecg2SkqaQVAFgg1ShMAbisS4OwEkYpRknTGINqXguE6Ul2vvOtvdnoIbh0sWvtjdPbgg8rbUK6cwuaKSIMLpXEkjFclpUFaoFUCnhTSkqSV7HzilcwTNWe22oadCqtJh1BU1wSJRP_4p_8a_d5sT3dh0knlqKEv9rhie2gttCPwbR7qv2d3q31yl9qqTghlCWD0xuD4L9OEEfduWihbU0PfoqacMYUI1SIhD6_h278FNIfzlRJKJZCkD_UyqT3cX3j07l2NtULrlTJJFczdfYXKo0aOmdTVhuX6nuCZ3cb_d3hbRwTIHeATYmMARqdMmVG5-e-Xasx0nPy9S75OiVfb5OvaZKSe9Jb9_-IfgHMTAek |
| CitedBy_id | crossref_primary_10_3233_ADR_220098 crossref_primary_10_3390_antiox13080926 crossref_primary_10_3390_cells12202459 crossref_primary_10_1016_j_nbd_2024_106441 crossref_primary_10_1126_scitranslmed_adg4122 crossref_primary_10_3233_JAD_221015 crossref_primary_10_1016_j_ijantimicag_2024_107137 crossref_primary_10_4103_NRR_NRR_D_23_01403 crossref_primary_10_3233_ADR_230025 crossref_primary_10_1186_s13024_023_00638_z crossref_primary_10_3390_pharmaceutics15082052 crossref_primary_10_3389_fneur_2023_1287545 crossref_primary_10_1093_brain_awac158 crossref_primary_10_3233_JAD_230792 crossref_primary_10_1002_alz_14375 crossref_primary_10_1038_s43587_023_00550_7 crossref_primary_10_1038_s41398_023_02475_6 crossref_primary_10_1186_s12974_023_02973_w crossref_primary_10_1021_acschemneuro_4c00339 crossref_primary_10_1016_j_heliyon_2024_e41266 crossref_primary_10_1111_cns_14857 crossref_primary_10_2174_0113894501320096240627071400 crossref_primary_10_1007_s13311_023_01370_8 crossref_primary_10_1002_alz_12713 crossref_primary_10_1016_j_neuron_2025_02_014 crossref_primary_10_1186_s13024_022_00540_0 crossref_primary_10_1002_alz_13449 crossref_primary_10_3390_bios15020085 crossref_primary_10_37349_en_2025_100675 crossref_primary_10_1002_alz_14103 crossref_primary_10_1007_s00018_022_04614_6 crossref_primary_10_1080_14737159_2023_2289553 crossref_primary_10_1016_j_arr_2023_102046 crossref_primary_10_1016_j_nbas_2022_100054 crossref_primary_10_1016_j_xcrm_2024_101669 crossref_primary_10_1080_19490976_2024_2323752 crossref_primary_10_1093_brain_awad213 crossref_primary_10_1038_s41588_025_02136_y |
| Cites_doi | 10.1176/ajp.141.11.1356 10.1038/ng.3643 10.1038/s41398-020-01074-z 10.1038/nn.3639 10.1152/ajpendo.00119.2007 10.1007/s00401-009-0627-8 10.1093/brain/awv029 10.1007/s00401-017-1685-y 10.1016/j.jmb.2019.01.023 10.1074/jbc.M309561200 10.1212/WNL.43.11.2412-a 10.1093/bioinformatics/btw392 10.1093/gigascience/giz082 10.1016/j.dadm.2015.06.008 10.1152/physrev.00050.2017 10.1096/fj.201902731RR 10.2967/jnumed.114.148981 10.2217/bmm.12.46 10.1186/s40035-021-00270-1 10.3233/JAD-150813 10.1016/j.neurobiolaging.2018.05.028 10.1016/j.neuron.2013.02.026 10.1093/brain/awaa325 10.1093/bioinformatics/btq466 10.1038/nature10821 10.1002/prca.201400178 10.1016/j.jalz.2010.03.013 10.7554/eLife.12748 10.1016/j.bbamcr.2013.02.020 10.1016/j.neurobiolaging.2017.10.017 10.1016/j.conb.2017.12.008 10.15252/emmm.201809695 10.1016/j.neurobiolaging.2009.07.002 10.1016/S0306-4522(00)00516-9 10.1523/JNEUROSCI.23-06-02112.2003 10.1016/j.jalz.2019.01.004 10.1016/j.neuint.2009.08.002 10.1523/JNEUROSCI.1860-14.2014 10.1016/j.jalz.2014.05.1754 10.1038/s41588-018-0311-9 10.1093/nar/gky1038 10.1186/s12864-015-2159-z 10.1093/nar/gkw377 10.1016/j.jalz.2018.02.018 10.1073/pnas.1010461107 10.1038/nature11405 10.1242/jcs.01323 10.1159/000067426 10.15252/emmm.201606210 10.3233/JAD-191254 10.1016/j.neuron.2019.05.002 10.3233/JAD-2011-101065 10.1101/2020.05.11.088591 10.1186/s40478-019-0837-9 10.1074/jbc.M402248200 10.1038/s41593-018-0291-1 10.1021/pr500893m 10.1016/S1474-4422(13)70194-7 10.1371/journal.pone.0023789 10.1093/nar/gkaa1113 10.1186/1750-1326-8-38 10.1093/brain/awq258 10.1038/nature13163 10.1016/j.neuron.2018.02.015 10.1126/science.abb8255 10.1016/j.nbd.2018.05.020 10.1016/j.jalz.2015.11.002 10.1242/jcs.1125880 10.1074/mcp.M114.041533 10.1016/0022-3956(75)90026-6 10.1093/jnen/nlw061 10.1002/pro.3647 10.1021/acs.jproteome.8b00809 10.1073/pnas.91.15.7104 10.1016/0026-2862(79)90020-7 10.1210/en.2008-1610 10.1038/ncb2050 10.1016/j.cmet.2017.06.021 10.1002/ana.26048 10.1016/0006-8993(88)90293-4 10.1161/STROKEAHA.111.627562 10.1074/jbc.M205227200 10.1084/jem.20131685 10.1186/s13195-018-0396-5 10.1038/emboj.2012.173 10.1126/science.1141736 10.1186/s12974-021-02182-3 10.1002/ana.21610 10.1093/database/baw100 10.1016/j.celrep.2019.01.023 10.1186/s12987-020-00196-2 10.1093/bioinformatics/btq340 10.1523/JNEUROSCI.0006-15.2015 |
| ContentType | Journal Article |
| Contributor | Smit, August B Tijms, Betty M Blennow, Kaj Teunissen, Charlotte E Zetterberg, Henrik Bertram, Lars Scheltens, Philip |
| Contributor_xml | – sequence: 1 givenname: August B surname: Smit fullname: Smit, August B – sequence: 2 givenname: Kaj surname: Blennow fullname: Blennow, Kaj – sequence: 3 givenname: Philip surname: Scheltens fullname: Scheltens, Philip – sequence: 4 givenname: Charlotte E surname: Teunissen fullname: Teunissen, Charlotte E – sequence: 5 givenname: Lars surname: Bertram fullname: Bertram, Lars – sequence: 6 givenname: Henrik surname: Zetterberg fullname: Zetterberg, Henrik – sequence: 7 givenname: Betty M surname: Tijms fullname: Tijms, Betty M |
| Copyright | 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2022 |
| Copyright_xml | – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2022 |
| CorporateAuthor | ADNI |
| CorporateAuthor_xml | – name: ADNI |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM AABEP ADTPV AOWAS D8T D91 ZZAVC F1U DOA |
| DOI | 10.1186/s13024-022-00521-3 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) SWEPUB Örebro universitet full text SwePub SwePub Articles SWEPUB Freely available online SWEPUB Örebro universitet SwePub Articles full text SWEPUB Göteborgs universitet DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 1750-1326 |
| EndPage | 16 |
| ExternalDocumentID | oai_doaj_org_article_4927a15981844155bce3ce2b9e6f5832 oai_gup_ub_gu_se_315298 oai_DiVA_org_oru_98330 PMC8962234 A699548692 35346299 10_1186_s13024_022_00521_3 |
| Genre | Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: Swedish state suppport for clinical research grantid: ALFGBG-720931 – fundername: Innovative Medicines Initiative grantid: 115372 – fundername: vlaamse impulsfinanciering voor netwerken voor dementie-onderzoek grantid: IWT #135043) – fundername: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung grantid: 320030_141179 – fundername: Alzheimerfonden grantid: (AF-930934 – fundername: zon-mw grantid: 733050512 – fundername: stichting alzheimer onderzoek grantid: 11020 – fundername: Medicinska Forskningsrådet grantid: 2018-02532 – fundername: H2020 European Research Council grantid: 681712 – fundername: zon-mw grantid: 733050824 – fundername: ; – fundername: ; grantid: 2018-02532 – fundername: ; grantid: 115372 – fundername: ; grantid: (AF-930934 – fundername: ; grantid: 733050824; 733050512 – fundername: ; grantid: ALFGBG-720931 – fundername: ; grantid: 681712 – fundername: ; grantid: IWT #135043) – fundername: ; grantid: 320030_141179 – fundername: ; grantid: 11020 |
| GroupedDBID | --- 0R~ 123 29M 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HH5 HMCUK HYE IAO IHR INH INR IPY ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW ~8M CGR CUY CVF ECM EIF NPM PMFND 3V. 7TK 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM 2VQ 4.4 AABEP ADTPV AHSBF AOWAS D8T D91 EJD H13 IPNFZ LGEZI LOTEE NADUK NXXTH RIG ZZAVC F1U PUEGO |
| ID | FETCH-LOGICAL-c676t-ec0cf2bc372ed1f66e842fb8c7ee1709f913ee68d5a0197a99432ffaa0d6d7013 |
| IEDL.DBID | M48 |
| ISSN | 1750-1326 |
| IngestDate | Wed Aug 27 01:22:00 EDT 2025 Thu Aug 21 06:41:41 EDT 2025 Thu Aug 21 06:33:48 EDT 2025 Thu Aug 21 17:46:16 EDT 2025 Thu Jul 10 22:24:34 EDT 2025 Fri Jul 25 23:15:33 EDT 2025 Tue Jun 17 21:45:48 EDT 2025 Tue Jun 10 20:43:38 EDT 2025 Thu Apr 03 07:00:10 EDT 2025 Thu Apr 24 22:51:23 EDT 2025 Tue Jul 01 01:59:05 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Biomarker discovery Cerebrospinal fluid proteomics Heterogeneity Neuronal plasticity Alzheimer's disease Molecular mechanisms |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c676t-ec0cf2bc372ed1f66e842fb8c7ee1709f913ee68d5a0197a99432ffaa0d6d7013 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-8008-9727 |
| OpenAccessLink | https://www.proquest.com/docview/2652318772?pq-origsite=%requestingapplication% |
| PMID | 35346299 |
| PQID | 2652318772 |
| PQPubID | 55149 |
| PageCount | 16 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_4927a15981844155bce3ce2b9e6f5832 swepub_primary_oai_gup_ub_gu_se_315298 swepub_primary_oai_DiVA_org_oru_98330 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8962234 proquest_miscellaneous_2644942377 proquest_journals_2652318772 gale_infotracmisc_A699548692 gale_infotracacademiconefile_A699548692 pubmed_primary_35346299 crossref_citationtrail_10_1186_s13024_022_00521_3 crossref_primary_10_1186_s13024_022_00521_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-03-28 |
| PublicationDateYYYYMMDD | 2022-03-28 |
| PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-28 day: 28 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Molecular neurodegeneration |
| PublicationTitleAlternate | Mol Neurodegener |
| PublicationYear | 2022 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | CR Jack Jr (521_CR11) 2018; 14 L Schnoder (521_CR70) 2020; 34 PH Kuhn (521_CR38) 2012; 31 X Cao (521_CR71) 2004; 279 AA Bergen (521_CR75) 2015; 16 WG Rosen (521_CR15) 1984; 141 521_CR61 D Wechsler (521_CR16) 1997 B Frost (521_CR73) 2014; 17 SI Rapoport (521_CR35) 1979; 18 KE Biron (521_CR52) 2011; 6 C Cruchaga (521_CR63) 2013; 78 S McCarthy (521_CR46) 2016; 48 JY Hwang (521_CR59) 2018; 48 AJ Saykin (521_CR45) 2010; 6 A Calderone (521_CR80) 2003; 23 Y Ihara (521_CR50) 1988; 459 B Dislich (521_CR37) 2015; 14 M Brkic (521_CR83) 2015; 35 DR Thal (521_CR85) 2019; 7 C Sato (521_CR7) 2018; 97 L Dayon (521_CR34) 2019; 18 H Wolburg (521_CR78) 2010; 119 G Banerjee (521_CR86) 2020; 74 I Bos (521_CR12) 2018; 10 SM Landau (521_CR42) 2015; 56 M Wu (521_CR65) 2021; 10 LM Shaw (521_CR19) 2009; 65 JW Prineas (521_CR84) 2016; 75 D Ferreira (521_CR4) 2018; 70 A Balestrini (521_CR90) 2010; 12 AG Vlassenko (521_CR55) 2010; 107 I Penna (521_CR87) 2013; 1833 BM Tijms (521_CR20) 2020; 143 A Haapasalo (521_CR41) 2011; 25 S Grote (521_CR33) 2016; 32 K Bossers (521_CR57) 2010; 133 MD Sweeney (521_CR76) 2019; 99 J Morris (521_CR17) 1993; 43 Y Zhang (521_CR31) 2014; 34 M del Campo (521_CR18) 2012; 6 MV Kuleshov (521_CR30) 2016; 44 SJ Vos (521_CR3) 2015; 138 CM Diaz-Garcia (521_CR91) 2017; 26 Y Chang (521_CR68) 2003; 278 M Neumeier (521_CR36) 2007; 293 DC Hondius (521_CR62) 2016; 12 S Hong (521_CR44) 2020; 10 A Lachmann (521_CR28) 2010; 26 T Arendt (521_CR66) 2001; 102 SJ Vos (521_CR5) 2013; 12 SM Landau (521_CR43) 2011; 32 C Gene Ontology (521_CR25) 2021; 49 VL Kouznetsova (521_CR58) 2019; 28 Y Deming (521_CR64) 2017; 133 AD Rouillard (521_CR29) 2016; 2016 RC von Rotz (521_CR72) 2004; 117 D Bertens (521_CR13) 2015; 11 PH Kuhn (521_CR39) 2016; 5 MJ Grothe (521_CR10) 2018; 141 T Brummer (521_CR40) 2019; 11 DS Spellman (521_CR22) 2015; 9 CW Chang (521_CR92) 2021; 371 K Yamada (521_CR9) 2014; 211 ME Seward (521_CR54) 2013; 126 TS Batth (521_CR21) 2014; 13 X Zhu (521_CR69) 2002; 11 T Lu (521_CR60) 2014; 507 F Marques (521_CR82) 2009; 150 AM Hartz (521_CR77) 2012; 43 SW Choi (521_CR48) 2019; 8 F Marques (521_CR79) 2013; 8 XY Sun (521_CR97) 2021; 18 P Bruni (521_CR88) 2002; 277 MJ Hawrylycz (521_CR32) 2012; 489 C Kyrousi (521_CR89) 2015; 142 H Mi (521_CR26) 2019; 47 F Koopmans (521_CR27) 2019; 103 HU Klein (521_CR74) 2019; 22 YY Leung (521_CR23) 2015; 1 K Meyer (521_CR8) 2019; 26 G Siano (521_CR95) 2019; 431 G Koch (521_CR96) 2016; 50 M Das (521_CR94) 2018; 117 M Bulk (521_CR51) 2018; 62 SM Greenberg (521_CR53) 1994; 91 KF Young (521_CR67) 2009; 55 MA Israel (521_CR56) 2012; 482 CJ Willer (521_CR47) 2010; 26 I Bos (521_CR2) 2019; 15 E Konijnenberg (521_CR6) 2021; 89 P Solar (521_CR81) 2020; 17 MF Folstein (521_CR14) 1975; 12 ED Roberson (521_CR93) 2007; 316 IE Jansen (521_CR49) 2019; 51 DJ Selkoe (521_CR1) 2016; 8 M Ashburner (521_CR24) 2000; 25 35550177 - Mol Neurodegener. 2022 May 13;17(1):37 |
| References_xml | – volume: 141 start-page: 1356 issue: 11 year: 1984 ident: 521_CR15 publication-title: Am J Psychiatry doi: 10.1176/ajp.141.11.1356 – volume: 48 start-page: 1279 issue: 10 year: 2016 ident: 521_CR46 publication-title: Nat Genet doi: 10.1038/ng.3643 – volume: 10 start-page: 403 issue: 1 year: 2020 ident: 521_CR44 publication-title: Transl Psychiatry doi: 10.1038/s41398-020-01074-z – volume: 17 start-page: 357 issue: 3 year: 2014 ident: 521_CR73 publication-title: Nat Neurosci doi: 10.1038/nn.3639 – volume: 293 start-page: E965 issue: 4 year: 2007 ident: 521_CR36 publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00119.2007 – volume: 119 start-page: 75 issue: 1 year: 2010 ident: 521_CR78 publication-title: Acta Neuropathol doi: 10.1007/s00401-009-0627-8 – volume: 138 start-page: 1327 issue: Pt 5 year: 2015 ident: 521_CR3 publication-title: Brain doi: 10.1093/brain/awv029 – volume: 133 start-page: 839 issue: 5 year: 2017 ident: 521_CR64 publication-title: Acta Neuropathol doi: 10.1007/s00401-017-1685-y – volume: 431 start-page: 873 issue: 4 year: 2019 ident: 521_CR95 publication-title: J Mol Biol doi: 10.1016/j.jmb.2019.01.023 – volume: 278 start-page: 51100 issue: 51 year: 2003 ident: 521_CR68 publication-title: J Biol Chem doi: 10.1074/jbc.M309561200 – volume: 43 start-page: 2412 year: 1993 ident: 521_CR17 publication-title: Neurology doi: 10.1212/WNL.43.11.2412-a – volume: 142 start-page: 3661 issue: 21 year: 2015 ident: 521_CR89 publication-title: Development – volume: 32 start-page: 3201 issue: 20 year: 2016 ident: 521_CR33 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btw392 – volume: 8 start-page: giz082 issue: 7 year: 2019 ident: 521_CR48 publication-title: Gigascience doi: 10.1093/gigascience/giz082 – volume: 1 start-page: 339 issue: 3 year: 2015 ident: 521_CR23 publication-title: Alzheimers Dement (Amst) doi: 10.1016/j.dadm.2015.06.008 – volume: 99 start-page: 21 issue: 1 year: 2019 ident: 521_CR76 publication-title: Physiol Rev doi: 10.1152/physrev.00050.2017 – volume: 34 start-page: 9628 issue: 7 year: 2020 ident: 521_CR70 publication-title: FASEB J doi: 10.1096/fj.201902731RR – volume: 56 start-page: 567 issue: 4 year: 2015 ident: 521_CR42 publication-title: J Nucl Med doi: 10.2967/jnumed.114.148981 – volume: 6 start-page: 419 issue: 4 year: 2012 ident: 521_CR18 publication-title: Biomark Med doi: 10.2217/bmm.12.46 – volume: 10 start-page: 45 issue: 1 year: 2021 ident: 521_CR65 publication-title: Transl Neurodegener doi: 10.1186/s40035-021-00270-1 – volume: 50 start-page: 605 issue: 2 year: 2016 ident: 521_CR96 publication-title: J Alzheimers Dis doi: 10.3233/JAD-150813 – volume: 70 start-page: 18 year: 2018 ident: 521_CR4 publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2018.05.028 – volume: 78 start-page: 256 issue: 2 year: 2013 ident: 521_CR63 publication-title: Neuron doi: 10.1016/j.neuron.2013.02.026 – volume: 143 start-page: 3776 issue: 12 year: 2020 ident: 521_CR20 publication-title: Brain doi: 10.1093/brain/awaa325 – volume: 26 start-page: 2438 issue: 19 year: 2010 ident: 521_CR28 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btq466 – volume: 482 start-page: 216 issue: 7384 year: 2012 ident: 521_CR56 publication-title: Nature doi: 10.1038/nature10821 – volume: 9 start-page: 715 issue: 7–8 year: 2015 ident: 521_CR22 publication-title: Proteomics Clin Appl doi: 10.1002/prca.201400178 – volume: 6 start-page: 265 issue: 3 year: 2010 ident: 521_CR45 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2010.03.013 – volume: 5 start-page: e12748 year: 2016 ident: 521_CR39 publication-title: Elife doi: 10.7554/eLife.12748 – volume: 1833 start-page: 1511 issue: 6 year: 2013 ident: 521_CR87 publication-title: Biochim Biophys Acta doi: 10.1016/j.bbamcr.2013.02.020 – volume: 62 start-page: 231 year: 2018 ident: 521_CR51 publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2017.10.017 – volume: 48 start-page: 193 year: 2018 ident: 521_CR59 publication-title: Curr Opin Neurobiol doi: 10.1016/j.conb.2017.12.008 – volume: 11 start-page: e9695 issue: 4 year: 2019 ident: 521_CR40 publication-title: EMBO Mol Med doi: 10.15252/emmm.201809695 – volume: 32 start-page: 1207 issue: 7 year: 2011 ident: 521_CR43 publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2009.07.002 – volume: 102 start-page: 723 issue: 4 year: 2001 ident: 521_CR66 publication-title: Neuroscience doi: 10.1016/S0306-4522(00)00516-9 – volume: 23 start-page: 2112 issue: 6 year: 2003 ident: 521_CR80 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.23-06-02112.2003 – volume: 15 start-page: 644 issue: 5 year: 2019 ident: 521_CR2 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2019.01.004 – volume: 55 start-page: 796 issue: 8 year: 2009 ident: 521_CR67 publication-title: Neurochem Int doi: 10.1016/j.neuint.2009.08.002 – volume: 34 start-page: 11929 issue: 36 year: 2014 ident: 521_CR31 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.1860-14.2014 – volume: 11 start-page: 511 issue: 5 year: 2015 ident: 521_CR13 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2014.05.1754 – volume: 51 start-page: 404 issue: 3 year: 2019 ident: 521_CR49 publication-title: Nat Genet doi: 10.1038/s41588-018-0311-9 – volume: 47 start-page: D419 issue: D1 year: 2019 ident: 521_CR26 publication-title: Nucleic Acids Res doi: 10.1093/nar/gky1038 – volume: 16 start-page: 956 year: 2015 ident: 521_CR75 publication-title: BMC Genomics doi: 10.1186/s12864-015-2159-z – volume: 44 start-page: W90 issue: W1 year: 2016 ident: 521_CR30 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkw377 – volume: 14 start-page: 535 issue: 4 year: 2018 ident: 521_CR11 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2018.02.018 – volume: 107 start-page: 17763 issue: 41 year: 2010 ident: 521_CR55 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1010461107 – volume: 489 start-page: 391 issue: 7416 year: 2012 ident: 521_CR32 publication-title: Nature doi: 10.1038/nature11405 – volume: 117 start-page: 4435 issue: Pt 19 year: 2004 ident: 521_CR72 publication-title: J Cell Sci doi: 10.1242/jcs.01323 – volume: 11 start-page: 270 issue: 5 year: 2002 ident: 521_CR69 publication-title: Neurosignals doi: 10.1159/000067426 – volume: 8 start-page: 595 issue: 6 year: 2016 ident: 521_CR1 publication-title: EMBO Mol Med doi: 10.15252/emmm.201606210 – volume: 74 start-page: 1189 issue: 4 year: 2020 ident: 521_CR86 publication-title: J Alzheimers Dis doi: 10.3233/JAD-191254 – volume: 103 start-page: 217 year: 2019 ident: 521_CR27 publication-title: Neuron. doi: 10.1016/j.neuron.2019.05.002 – volume: 25 start-page: 3 issue: 1 year: 2011 ident: 521_CR41 publication-title: J Alzheimers Dis doi: 10.3233/JAD-2011-101065 – ident: 521_CR61 doi: 10.1101/2020.05.11.088591 – volume: 7 start-page: 178 issue: 1 year: 2019 ident: 521_CR85 publication-title: Acta Neuropathol Commun doi: 10.1186/s40478-019-0837-9 – volume: 279 start-page: 24601 issue: 23 year: 2004 ident: 521_CR71 publication-title: J Biol Chem doi: 10.1074/jbc.M402248200 – volume: 22 start-page: 37 issue: 1 year: 2019 ident: 521_CR74 publication-title: Nat Neurosci doi: 10.1038/s41593-018-0291-1 – volume: 13 start-page: 6176 issue: 12 year: 2014 ident: 521_CR21 publication-title: J Proteome Res doi: 10.1021/pr500893m – volume: 12 start-page: 957 issue: 10 year: 2013 ident: 521_CR5 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(13)70194-7 – volume: 6 start-page: e23789 issue: 8 year: 2011 ident: 521_CR52 publication-title: PLoS One doi: 10.1371/journal.pone.0023789 – volume: 49 start-page: D325 issue: D1 year: 2021 ident: 521_CR25 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkaa1113 – volume: 8 start-page: 38 year: 2013 ident: 521_CR79 publication-title: Mol Neurodegener doi: 10.1186/1750-1326-8-38 – volume: 133 start-page: 3699 issue: Pt 12 year: 2010 ident: 521_CR57 publication-title: Brain doi: 10.1093/brain/awq258 – volume: 507 start-page: 448 issue: 7493 year: 2014 ident: 521_CR60 publication-title: Nature doi: 10.1038/nature13163 – volume: 97 start-page: 1284 issue: 6 year: 2018 ident: 521_CR7 publication-title: Neuron doi: 10.1016/j.neuron.2018.02.015 – volume: 371 start-page: eabb8255 issue: 6532 year: 2021 ident: 521_CR92 publication-title: Science doi: 10.1126/science.abb8255 – volume: 117 start-page: 181 year: 2018 ident: 521_CR94 publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2018.05.020 – volume: 25 start-page: 25 issue: 1 year: 2000 ident: 521_CR24 publication-title: The Gene Ontology Consortium Nat Genet – volume: 12 start-page: 654 issue: 6 year: 2016 ident: 521_CR62 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2015.11.002 – volume: 126 start-page: 1278 issue: Pt 5 year: 2013 ident: 521_CR54 publication-title: J Cell Sci doi: 10.1242/jcs.1125880 – volume: 14 start-page: 2550 issue: 10 year: 2015 ident: 521_CR37 publication-title: Mol Cell Proteomics doi: 10.1074/mcp.M114.041533 – volume: 12 start-page: 189 year: 1975 ident: 521_CR14 publication-title: J Psychiatr Res doi: 10.1016/0022-3956(75)90026-6 – volume: 75 start-page: 855 issue: 9 year: 2016 ident: 521_CR84 publication-title: J Neuropathol Exp Neurol doi: 10.1093/jnen/nlw061 – volume: 28 start-page: 1387 issue: 8 year: 2019 ident: 521_CR58 publication-title: Protein Sci doi: 10.1002/pro.3647 – volume: 18 start-page: 1162 issue: 3 year: 2019 ident: 521_CR34 publication-title: J Proteome Res doi: 10.1021/acs.jproteome.8b00809 – volume: 91 start-page: 7104 issue: 15 year: 1994 ident: 521_CR53 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.91.15.7104 – volume: 18 start-page: 105 issue: 1 year: 1979 ident: 521_CR35 publication-title: Microvasc Res doi: 10.1016/0026-2862(79)90020-7 – volume: 150 start-page: 2822 issue: 6 year: 2009 ident: 521_CR82 publication-title: Endocrinology doi: 10.1210/en.2008-1610 – volume-title: Wechsler Memory Scale- year: 1997 ident: 521_CR16 – volume: 12 start-page: 484 issue: 5 year: 2010 ident: 521_CR90 publication-title: Nat Cell Biol doi: 10.1038/ncb2050 – volume: 26 start-page: 361 issue: 2 year: 2017 ident: 521_CR91 publication-title: Cell Metab doi: 10.1016/j.cmet.2017.06.021 – volume: 89 start-page: 987 year: 2021 ident: 521_CR6 publication-title: Ann Neurol. doi: 10.1002/ana.26048 – volume: 459 start-page: 138 issue: 1 year: 1988 ident: 521_CR50 publication-title: Brain Res doi: 10.1016/0006-8993(88)90293-4 – volume: 43 start-page: 514 issue: 2 year: 2012 ident: 521_CR77 publication-title: Stroke doi: 10.1161/STROKEAHA.111.627562 – volume: 277 start-page: 35481 issue: 38 year: 2002 ident: 521_CR88 publication-title: J Biol Chem doi: 10.1074/jbc.M205227200 – volume: 211 start-page: 387 issue: 3 year: 2014 ident: 521_CR9 publication-title: J Exp Med doi: 10.1084/jem.20131685 – volume: 10 start-page: 64 issue: 1 year: 2018 ident: 521_CR12 publication-title: Alzheimers Res Ther doi: 10.1186/s13195-018-0396-5 – volume: 31 start-page: 3157 issue: 14 year: 2012 ident: 521_CR38 publication-title: EMBO J doi: 10.1038/emboj.2012.173 – volume: 316 start-page: 750 issue: 5825 year: 2007 ident: 521_CR93 publication-title: Science doi: 10.1126/science.1141736 – volume: 18 start-page: 131 issue: 1 year: 2021 ident: 521_CR97 publication-title: J Neuroinflammation doi: 10.1186/s12974-021-02182-3 – volume: 65 start-page: 403 issue: 4 year: 2009 ident: 521_CR19 publication-title: Ann Neurol doi: 10.1002/ana.21610 – volume: 2016 start-page: baw100 year: 2016 ident: 521_CR29 publication-title: Database (Oxford) doi: 10.1093/database/baw100 – volume: 26 start-page: 1112 issue: 5 year: 2019 ident: 521_CR8 publication-title: Cell Rep doi: 10.1016/j.celrep.2019.01.023 – volume: 17 start-page: 35 issue: 1 year: 2020 ident: 521_CR81 publication-title: Fluids Barriers CNS doi: 10.1186/s12987-020-00196-2 – volume: 26 start-page: 2190 issue: 17 year: 2010 ident: 521_CR47 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btq340 – volume: 141 start-page: 2755 issue: 9 year: 2018 ident: 521_CR10 publication-title: Brain – volume: 35 start-page: 12766 issue: 37 year: 2015 ident: 521_CR83 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.0006-15.2015 – reference: 35550177 - Mol Neurodegener. 2022 May 13;17(1):37 |
| SSID | ssj0047005 |
| Score | 2.5262203 |
| Snippet | Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from... Background Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from... Background Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer’s disease (AD) and is considered to result from... BACKGROUND: Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from... Abstract Background Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer’s disease (AD) and is considered to result... |
| SourceID | doaj swepub pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 27 |
| SubjectTerms | adult Advertising executives Alzheimer Disease - cerebrospinal fluid Alzheimer Disease - pathology Alzheimer's disease amyloid precursor protein Apolipoprotein E Apolipoproteins Biomarker discovery Biomarkers Biomarkers - cerebrospinal fluid Biotechnology industry Blood-brain barrier cell-cycle progression Cerebrospinal fluid Cerebrospinal fluid proteomics Cognition & reasoning Consortia Dementia Dementia disorders Diagnostic imaging enrichment Gene expression Gene regulation generation Genotype & phenotype Heterogeneity Humans Mass spectrometry Medical imaging Memory Metabolism Molecular mechanisms Neurodegeneration Neurodegenerative diseases Neuroimaging Neuronal Plasticity Neurons Neuroplasticity Neurosciences Neurosciences & Neurology Neurovetenskaper Peptides Proteins Proteomics Quality control rest Scientific imaging Single nucleotide polymorphisms Single-nucleotide polymorphism Software Target marketing Tau protein tau Proteins - cerebrospinal fluid transcription Transcription factors wide |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQT1wQUH4CBRkJygFF3diOYx-XQlUhwYmi3izHmbQr7aarZHMoJ16D1-NJmHGyqwYQXDgmnpFiz9jzjTP-zNhLq2StMZKnmcplqnxVpnR8Ex-FJzIUY0vaGvj4SZ-eqQ_n-fmNq76oJmygBx4G7khZUXiMuRhYCPrnZQAZQJQWdJ2jO9LqizFvm0wNa7Aq0Lm2R2SMPuro95xKqXKd9kGzVE7CUGTr_31NvhGUfi2YnNCKxlB0cpfdGTEknw_ffo_dguY-2583mD-vrvkhj1Wdcbt8n62PocW0l24HIZ162S8qvvE9X1K1UMd9C9yPJoKK07Ys92VDSHbJI9klqa0RY1P59eaar6iep-34ouHz5ddLWKyg_fHte8fHXz0P2NnJ-8_Hp-l4y0IadKE3KYRZqEUZZCGgymqtwShRlyYUAFkxs7XNJIA2Ve4RDhbeonlFXXs_q3RVIIJ8yPaaqwYeM15bACkVwaJMhUqUlP_MKuNBorlsSFi2HXQXRgpyuglj6WIqYrQbDOXQUC4aysmEvdnprAcCjr9KvyVb7iSJPDu-QJdyo0u5f7lUwl6TJzia4vh5wY8nFbCTRJbl5ppI9Iy2KHkwkcSpGabNW19y49LQOaEx988MZjUJe7FrJk0qd2vgqicZhRNFyKJI2KPB9XZdkrlUGkFEwoqJU076PG1pFpeRONxYjWhQJezV4L4TlXeLL_M4TFdt76yRcpawwz_IXfRrh68ueteBkwj_rHnyP0b9Kbst4gSVqTAHbG_T9vAMAd-mfB7n9k8P3VNf priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagXLggoPyEFmQkKAcUdWM7_jmhpVBVSHCiaG-W4zjblXaz22RzaE-8Bq_HkzDjzS4EUI-Jx1KcmbG_GY8_E_LKCF5JWMnTTOQ8Fa4sUjy-CY_MIRmKNgWmBj5_kWfn4tMkn_QJt7Yvq9zOiXGiLpcec-THTELIlGkAg-9WlyneGoW7q_0VGrfJHaQuw5IuNdkFXEKBiW0Pymh53OImnUixfh2zoVnKB4tR5Oz_d2b-Y2n6u2xyQC4aF6TT--RejyTpeKP6B-RWqB-S_XENUfTiih7RWNsZk-b7ZHUSGgh-8Y4Q7FPNu1lJ166jc6wZaqlrAnW9okJJMTlLXVEjnp3TSHmJ3VaAtLEIe31FF1jV07R0VtPx_PoizBah-fn9R0v7DZ9H5Pz049eTs7S_ayH1Usl1GvzIV6zwXLFQZpWUQQtWFdqrEDI1MpXJeAhSl7kDUKicASWzqnJuVMpSAY58TPbqZR2eElqZEDgXCI4y4UtWYBQ0KrUL3ARpfEKy7U-3vicix_sw5jYGJFrajaIsKMpGRVmekLe7PqsNDceN0u9RlztJpNCOL5bN1PYeaYVhygGYA8SCMWVe-MB9YAV8Y5XDPJeQN2gJFh0dPs-7_rwCDBIps-xYIpWelgYkDweS4KB-2Ly1JdtPEK39bc4Jeblrxp5Y9FaHZYcyAtyFcaUS8mRjersh8ZwLCVAiIWpglIMxD1vq2UWkD9dGAiYUCXm9Md9Blw-zb-P4m5ZNZ43mfJSQo__ITbuVhVfTzrbBcgCBRj-7eZwH5C6LrsdTpg_J3rrpwnMAdOviRfTaX7sqS9I priority: 102 providerName: ProQuest |
| Title | Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35346299 https://www.proquest.com/docview/2652318772 https://www.proquest.com/docview/2644942377 https://pubmed.ncbi.nlm.nih.gov/PMC8962234 https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-98330 https://gup.ub.gu.se/publication/315298 https://doaj.org/article/4927a15981844155bce3ce2b9e6f5832 |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELf28cILAsZHxqiMBNsDCiSx448HhLKxaZq0CQFFfbOcxOkqtelIG4nx13PnphWBCfEUJT5Hse8u97vz-UzIK81ZJcCShzFPWchtmYe4fRNuE4vFUJTOMTRweSXOh_xilI62yPq4o24CF3e6dnie1LCZvv3x_fYDKPx7r_BKvFvg4hsPMS8do5xxyLbJLlgmiYp6yTerClxGPqURLGYUghcm1pto7nxHz1D5ev5__7V_M1t_plT2Co96Y3X2gNzvUCbNVmLxkGy5-hHZy2rwsGe39JD6vE8fUN8j9YlrwDHG80OwTzVtJyVd2pZOMZ9oQW3jqO2Y6EqKgVtq8xqx7pT6cpjY7QZQOCZoL2_pDDN-mgWd1DSb_rx2k5lrjha0Wwp6TIZnp19PzsPuFIawEFIsQ1dERZXkBZOJK-NKCKd4UuWqkM7FMtKVjplzQpWpBbgorQb2J1VlbVSKUgLCfEJ26nntnhFaaecY4wibYl6USY7-UVQq65h2QhcBiddTboquRDmelDE13lVRwqzYZIBNxrPJsIC82fS5WRXo-Cf1MXJyQ4nFtf2DeTM2na4arhNpAeYBlkFvM80LxwqX5PCNVQp_wIAcoRwYFEr4vMJ2OxlgkFhMy2QCi-wpoYHyoEcJqlv0m9eSZNaSbxKRAuZW4PUE5OWmGXtiOlzt5i3ScFCkhEkZkKcrwdsMiaWMCwAZAZE9keyNud9ST659YXGlBaBFHpDXK-Htdfk4-Zb5aZo3rdGKsSggh3fQjdsbA4_GrVk4wwAearX_HwN5Tu4lXvtYmKgDsrNsWvcC8N4yH5BtOZIDsptlF18u4Hp8evXp88BHTwZewX8BptJV9Q |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKe4ALAspPoICRaDmgqBvb69gHhLZ_aumPEGpRb8ZxnHalbXZJNkLlxGvwEjwUT8JMNlkIoN563HhmFWfGM9_Y4xlCXmrBMwmePIxEn4fCpkmI1zfhJ7NYDEXpBLcGDo_k7ol4d9o_XSA_2rswmFbZ2sTaUKdjh3vk60xCyBQpAINvJ59D7BqFp6ttC42ZWuz7yy8QspVv9rZAvquM7Wwfb-6GTVeB0MlYTkPvei5jieMx82mUSemVYFmiXOx9FPd0piPuvVRp3wL8ia2G6bAss7aXyjQGxAT_e4MsCQ6hzCJZ2tg-ev-htf0iBqVur-YouV7isaAIMWMe91-jkHfcX90l4F9f8Icz_DtRs1POtHaBO3fI7Qa70sFM2e6SBZ_fI8uDHOL2i0u6Ruts0nqbfplMNn0B4TZ2JUGebFQNUzq1FR1hllJJbeGpbVTDpxS3g6lNckTQI1oX2US2CWB7TPueXtILzCMqSjrM6WD09dwPL3zx89v3kjZHTPfJybXI4QFZzMe5f0Ropr3nXCAci4RLWYJxVy9V1nPtpXYBidqPblxT-hw7cIxMHQIpaWaCMiAoUwvK8IC8nvNMZoU_rqTeQFnOKbFod_1gXJyZxgYYoVlsAT4CRsIotp84z51nCbxj1gfLGpBXqAkGTQu8nrPNDQmYJBbpMgOJxfuU1EC50qEEk-C6w60umcYkleb3AgrIi_kwcmKaXe7HFdIIWKCMx3FAHs5Ubz4l3udCAngJSNxRys6cuyP58LwuWK60BBQqArI6U98Oy9bw46D-TOOiMlpx3gvI2n_ozqqJgUdnlSm94QA7tXp89Tyfk5u7x4cH5mDvaP8JucXqZchDplbI4rSo_FOAk9PkWbOGKfl03WbjF735ixc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cerebrospinal+fluid+tau+levels+are+associated+with+abnormal+neuronal+plasticity+markers+in+Alzheimer%27s+disease&rft.jtitle=Molecular+neurodegeneration&rft.au=Visser%2C+Pieter+Jelle&rft.au=Reus%2C+Lianne+M&rft.au=Gobom%2C+Johan&rft.au=Jansen%2C+Iris&rft.date=2022-03-28&rft.issn=1750-1326&rft.eissn=1750-1326&rft.volume=17&rft.issue=1&rft.spage=27&rft_id=info:doi/10.1186%2Fs13024-022-00521-3&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1326&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1326&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1326&client=summon |